Genfit S.A. (GNFT)
NASDAQ: GNFT · Real-Time Price · USD
3.885
-0.165 (-4.07%)
Nov 5, 2025, 4:00 PM EST - Market closed
Genfit Revenue
Genfit had revenue of 35.54M EUR in the half year ending June 30, 2025, with 135.16% growth. This brings the company's revenue in the last twelve months to 45.13M, down -43.93% year-over-year. In the year 2024, Genfit had annual revenue of 70.69M with 105.01% growth.
Revenue (ttm)
45.13M EUR
Revenue Growth
-43.93%
P/S Ratio
3.80
Revenue / Employee
250,694 EUR
Employees
180
Market Cap
201.19M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 70.69M | 36.21M | 105.01% |
| Dec 31, 2023 | 34.48M | 8.24M | 31.38% |
| Dec 31, 2022 | 26.25M | -59.11M | -69.25% |
| Dec 31, 2021 | 85.36M | 76.67M | 883.14% |
| Dec 31, 2020 | 8.68M | -30.29M | -77.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GNFT News
- 6 days ago - GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market - GlobeNewsWire
- 8 days ago - GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025 - GlobeNewsWire
- 6 weeks ago - GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD - GlobeNewsWire
- 4 months ago - Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - GlobeNewsWire
- 5 months ago - GENFIT: June 17, 2025 Combined Shareholders Meeting Results - GlobeNewsWire
- 5 months ago - GENFIT Reports First Quarter 2025 Financial Information - GlobeNewsWire
- 6 months ago - GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy - GlobeNewsWire